ISSN: 2455-8109

International Journal of Farmacia (IJF)

IJF |Vol. 11 | Issue 3 | Jul - Sept -2025

www.ijfjournal.com

DOI : https://doi.org/10.61096/ijf.v11.iss3.2025.182-187

Biological Assessment of Coenzyme Q10 Nanoemulsion for Cutaneous Aging: Antioxidant Screening, Matrix-Associated Enzyme Inhibition and Cytocompatibility Protocol

[1]*Ravi Sondur, [2]S.K.Misra

[1] *Research Scholar, Department of Pharmaceutics, SOPS, CSJM University, Kanpur*

[2] *Research Guide, Department of Pharmaceutics, SOPS, CSJM University, Kanpur*

[*]Author for Correspondence: **Ravi Sondur***
Email: ravisondur65@gmail.com

Published on:

18.09.2025

Published by:

Futuristic Publications

Creative Commons Attribution 4.0 International License.

Abstract: Oxidative injury and dysregulated extracellular matrix turnover contribute to age-associated changes in skin. Coenzyme Q10 (CoQ10) is a lipid-associated redox-active molecule that provides a rationale for investigating topical antioxidant formulations. The objective of this protocol and literature-evidence analysis is to define a biological assessment strategy for a CoQ10-loaded nanoemulsion, emphasizing complementary chemical, enzymatic and cellular endpoints. The proposed investigations comprise DPPH and ABTS radical-scavenging assays, collagenase and elastase inhibition, cytocompatibility screening in human cutaneous cells, and evaluation of intracellular oxidative stress, type I procollagen and matrix metalloproteinase-1 responses. Blank nanoemulsion, reference CoQ10, conventional CoQ10 formulation and assay-specific controls are incorporated to distinguish active-associated effects from vehicle contributions and analytical interference. Published observations reproduced in the source thesis report skin-surface ubiquinol values of 0.52 ± 0.02 ng/mm² in untreated skin and 0.57 ± 0.03 and 0.58 ± 0.02 ng/mm² following two topical formulations. The corresponding differences from the untreated mean are 9.62% and 11.54%, respectively. A stressed-skin antioxidant capacity of 1.58 ± 0.03 mmol/L Trolox was also reported for the second formulation. These are external literature observations, not measurements of the proposed nanoemulsion. No primary biological results were available in the thesis. The proposed framework establishes a basis for future experimental evaluation without equating chemical antioxidant activity or cellular responses with demonstrated clinical anti-aging efficacy.

Keywords: Coenzyme Q10; DPPH; ABTS; Collagenase; Elastase; Cytocompatibility; Oxidative stress; Research protocol.

INTRODUCTION

Cutaneous aging reflects interacting chronological and environmental influences. Oxidative stress, mitochondrial dysfunction, cellular senescence and altered extracellular matrix metabolism contribute to changes in tissue maintenance. Ultraviolet exposure may accelerate these processes, leading to altered collagen turnover and deterioration of skin mechanical properties [1]. Biological evaluation of an antioxidant formulation therefore requires several complementary endpoints rather than a single cosmetic efficacy measurement.

CoQ10 participates in mitochondrial electron transport and redox-associated processes. Its reduced form, ubiquinol, is relevant to lipid-associated antioxidant defense. Published investigations of topical CoQ10 provide a biological basis for examining its potential cutaneous effects [2,3]. Nevertheless, evidence from previously studied products cannot establish the performance of a newly proposed

nanoemulsion. The biological activity of that candidate must be assessed in relation to its own composition, exposure conditions and controls.

The dermal extracellular matrix is maintained by coordinated synthesis, organization and degradation of structural proteins. Changes in collagen-associated processes and elastic tissue organization are relevant to skin aging. Enzyme inhibition assays provide a means of screening defined proteolytic activities, whereas fibroblast models permit investigation of selected matrix-associated responses. These approaches address different levels of biological organization and should not be treated as interchangeable evidence.

The principal aim of the present manuscript is to establish a source-based protocol for evaluating the antioxidant activity, matrix-associated biochemical responses and cellular compatibility of the candidate CoQ10 nanoemulsion. The available published numerical observations are examined separately to identify the biological rationale for the proposed investigations. Formulation optimization, physicochemical characterization, storage profiles, membrane release and skin-distribution datasets are outside the scope of this companion paper.

STUDY METHODOLOGY

Study design and source of information

This manuscript is a prospective laboratory research protocol accompanied by a descriptive analysis of external literature values reproduced in the supplied thesis. The biological procedures are based on thesis Sections 4.16–4.18, 7.8–7.17, 8.10 and 9.7. No new laboratory experiments or human interventions were conducted for this manuscript. Primary dose–response measurements, biological replicate records and statistical comparison outputs were not available.

Table 1: Proposed biological evaluation domains

Domain	Selected endpoint	Scientific purpose
Chemical antioxidant activity	DPPH and ABTS inhibition	Radical-scavenging response
Matrix-associated enzymes	Collagenase and elastase inhibition	Defined proteolytic activity
Cell compatibility	Relative viability	Concentration-dependent tolerability
Cellular oxidative stress	Relative ROS-associated response	Stress-related cellular changes
Matrix biomarkers	Type I procollagen; MMP-1	Selected synthesis and degradation pathways

All endpoints are prospective.

DPPH radical-scavenging assay

The DPPH method will assess the capacity of CoQ10-containing samples to reduce a stable nitrogen-centered radical under standardized chemical conditions [4]. A compatible solvent and extraction procedure will be qualified to recover and solubilize CoQ10. Test extracts will be prepared over a concentration range established through preliminary experiments, mixed with DPPH reagent and incubated under controlled conditions protected from excessive light. Absorbance will be recorded near 515–517 nm following qualification of the analytical wavelength.

Trolox will serve as the reference antioxidant. Blank nanoemulsion extracts and appropriate sample blanks will be evaluated to account for excipient-related responses, turbidity and optical interference. Active-loaded and comparator preparations will be compared at equivalent CoQ10 concentrations. The percentage inhibition will be calculated from appropriately corrected absorbances as follows:

$$\text{Inhibition (\%)} = [(A_{\square} - A_s) / A_{\square}] \times 100$$

$A_{\square}$ is the corrected control absorbance and A_s is the corrected sample absorbance. IC_{50} denotes the concentration corresponding to 50% inhibition and will be estimated only if the measured concentration range adequately supports that endpoint.

ABTS radical-cation decolorization assay

The ABTS assay will complement the DPPH method using a radical-cation system [5]. ABTS radical cations will be generated using an established procedure involving ABTS and potassium persulfate. The reagent will be diluted to a qualified starting absorbance before exposure to selected concentrations of CoQ10-containing extracts. Absorbance changes will be monitored near 734 nm after a defined reaction period. Trolox will be used as the reference antioxidant, with blank and solvent controls included as appropriate.

Table 2: Proposed analytical conditions for antioxidant screening

Parameter	DPPH	ABTS
Wavelength	515–517 nm	Approximately 734 nm
Reference antioxidant	Trolox	Trolox
Sample	CoQ10 nanoemulsion extract	CoQ10 nanoemulsion extract
Control	Blank nanoemulsion extract	Blank and solvent controls
Outcome	Inhibition (%); IC_{50}	Inhibition (%); IC_{50} or Trolox-equivalent activity
Concentration range	Pilot-defined	Pilot-defined

Differences between the two assays will be interpreted in relation to reaction chemistry, solvent composition and assay conditions. Concordant responses may strengthen the chemical screening evidence, but neither method represents the complete antioxidant system of living skin.

Collagenase inhibition assay

A qualified collagenase preparation will be incubated with a compatible chromogenic or fluorogenic substrate in a defined reaction buffer. The enzyme source and substrate will be selected in accordance with the mechanistic objective. The CoQ10 nanoemulsion, blank nanoemulsion and CoQ10 reference preparation will be evaluated at predefined concentrations. An appropriate reference inhibitor will be included to demonstrate assay responsiveness. Initial reaction-rate measurements are preferred when the analytical signal varies with incubation time.

The percentage inhibition will be calculated relative to the corrected enzyme-control response. Substrate blanks and formulation interference controls will distinguish reductions in enzyme-associated signal from changes caused by sample color, turbidity or substrate interactions. Any observed inhibition will be attributed only to the enzyme preparation actually studied. In particular, bacterial collagenase activity cannot be treated as equivalent to human matrix metalloproteinase activity.

Elastase inhibition assay

A corresponding enzyme–substrate system will be selected to investigate elastase-associated proteolytic activity. The active-loaded formulation will be examined alongside blank vehicle and suitable reference controls. Reaction conditions, enzyme activity, concentration range and detection method will be defined during assay qualification. The outcome will be reported as percentage inhibition, with an IC_{50} estimate where the response range is adequate. A decrease in isolated elastase activity will not establish improvement in skin elasticity.

Table 3: Proposed matrix-associated enzyme evaluation

Component	Collagenase	Elastase
Enzyme	Qualified collagenase	Qualified elastase
Substrate	Compatible chromogenic or fluorogenic substrate	Compatible elastase substrate
Test material	CoQ10 nanoemulsion	CoQ10 nanoemulsion
Controls	Enzyme, substrate, vehicle and reference inhibitor	Enzyme, substrate, vehicle and reference inhibitor
Readout	Corrected reaction rate	Corrected enzyme activity
Endpoint	Inhibition (%); IC_{50} if supported	Inhibition (%); IC_{50} if supported

Exploratory tyrosinase evaluation

Tyrosinase inhibition may be considered only if a pigmentation-related objective is explicitly incorporated. An appropriate enzyme source and compatible substrate such as L-DOPA may be selected, with substrate and vehicle controls. Mushroom tyrosinase responses, if measured, would not directly establish inhibition of human melanogenesis. This endpoint remains exploratory rather than central to the antioxidant-focused investigation.

Cell culture and cytocompatibility

Authenticated human dermal fibroblasts will be considered for investigations of extracellular matrix-associated responses and cellular oxidative stress. Human keratinocytes may be selected for complementary epidermal compatibility assessment. Cell identity, passage number, culture conditions and mycoplasma testing status will be documented. Incubation will generally be maintained at approximately 37°C with 5% carbon dioxide, where appropriate to the selected cell system.

The candidate formulation will be diluted into a cell-compatible medium. Exposure concentrations and durations will be defined through pilot experiments. Blank vehicle will be tested at excipient concentrations equivalent to those of the active-loaded preparation. A metabolic activity assay such as an MTT-type method may be considered only after assessing interference from CoQ10 and excipients. Membrane integrity measurements or microscopy may complement the metabolic readout.

$$\text{Relative viability (\%)} = (\text{Corrected treated signal} / \text{Corrected control signal}) \times 100$$

Table 4: Proposed cytocompatibility groups

Group	Treatment	Purpose
C1	Untreated cells	Baseline response
C2	Blank nanoemulsion	Vehicle-associated effects
C3	CoQ10 nanoemulsion	Test formulation compatibility
C4	Conventional CoQ10 formulation	Comparator
C5	Positive cytotoxicity control	Assay responsiveness
C6	Cell-free formulation blank	Analytical interference

Biological replication and safety screening

A minimum of three independent biological experiments is proposed for preliminary evaluation, with suitable technical replication. The final sample size will be justified using pilot variability and the intended comparisons. Technical measurements within one independent experiment must not be counted as separate biological experiments. Relative viability will be interpreted in relation to concentration, duration and the assay mechanism rather than as comprehensive proof of safety.

A qualified reconstructed human epidermis model may subsequently be used to assess irritation-related responses under the applicable OECD TG 439 protocol [6]. Any human patch testing would require sufficient preliminary safety evidence, ethics approval, informed consent and qualified medical supervision. No irritation, sensitization or human tolerability results are available in the source thesis.

Intracellular oxidative stress and matrix-associated biomarkers

Cellular antioxidant evaluation will employ a qualified fluorescent or biochemical readout following a controlled oxidative stress challenge. Treatment concentrations will be selected from preliminary viability investigations. Untreated cells, stress-exposed controls, blank nanoemulsion, reference CoQ10 and active-loaded nanoemulsion will be included. The selected signal will be corrected for cell number, viability and analytical interference before interpretation.

Type I procollagen may be assessed by an appropriate immunochemical or molecular method. MMP-1 expression or catalytic activity may also be examined in a fibroblast model. Transcriptional expression, enzyme abundance and enzyme activity represent distinct endpoints and must be reported separately. Changes in procollagen response cannot establish deposition of mature collagen in an organized dermal matrix.

Table 5: Proposed cellular biomarker reporting plan

Biological target	Readout	Interpretation boundary
Oxidative stress	Relative intracellular ROS-associated signal	Model-specific stress response
Antioxidant defense	Selected enzyme activity	Cellular redox-associated response
Collagen synthesis	Type I procollagen	Matrix-associated biosynthesis marker
Collagen degradation	MMP-1 expression or activity	Selected remodeling pathway
Cellular senescence	Selected validated markers	Age-associated cellular response

Statistical analysis

Independent experimental observations will be summarized as mean ± standard deviation with the number of independent experimental units and, where appropriate, 95% confidence intervals. Concentration–response models may be used to estimate IC_{50} values where the tested range adequately spans 50% inhibition. Model assumptions, variance and dependence will be examined before inferential comparisons. Appropriate adjustment for multiple comparisons will be considered. The significance threshold and principal endpoints will be specified before confirmatory experiments.

RESULTS: EXTERNAL LITERATURE EVIDENCE

The source thesis does not supply primary biological observations for the proposed nanoemulsion. It reproduces selected results from published topical CoQ10 research [3] as external evidence. The following analysis is restricted to those reported summary values. No primary statistical tests, IC_{50} estimates, cell survival percentages or enzyme inhibition values can be calculated for the candidate formulation.

RESULTS (continued)

Table 6: Published skin-surface ubiquinol observations

Published treatment condition	Reported ubiquinol (ng/mm²)	Difference from untreated mean	Relative difference (%)
Untreated skin	0.52 ± 0.02	Reference	Reference
Topical formula 1	0.57 ± 0.03	+0.05	+9.62
Topical formula 2	0.58 ± 0.02	+0.06	+11.54



Fig 1: Published mean skin-surface ubiquinol values

Compared with the untreated mean, the first topical formula was associated with a descriptive increase of 0.05 ng/mm² and the second with 0.06 ng/mm². The relative differences were calculated as [(treated mean − untreated mean)/untreated mean] × 100. These differences do not establish statistical significance, since the necessary experimental design and replicate information are not given in the thesis table.

Table 7: Published stressed-skin antioxidant capacity

Condition	Reported value	Data interpretation
Topical formula 2 in stressed-skin experiment	1.58 ± 0.03 mmol/L Trolox	External antioxidant-capacity observation; no untreated comparator value supplied

The published antioxidant-capacity observation provides a rationale for further study but cannot be used as the expected response of the proposed nanoemulsion. The reported formulas are not established as compositionally equivalent to the candidate under investigation.

DISCUSSION

The proposed biological program separates chemical radical scavenging from matrix-associated enzyme activity and cellular responses. DPPH and ABTS assays provide useful early screening but are sensitive to the reaction environment and sample preparation. Proper extraction, matched concentrations and formulation blanks are essential to determine whether a response is attributable to CoQ10. Chemical activity alone cannot establish protection against cutaneous oxidative injury.

The enzyme studies address selected biochemical activities associated with matrix turnover. Their relevance depends on the enzyme source, substrate and detection method. Cellular assessment extends this framework by testing compatibility and stress-associated responses in human cutaneous cell models. However, monolayer cultures lack the organized architecture and mechanical characteristics of living skin. The combined assays therefore provide complementary mechanistic evidence, not a direct measurement of wrinkle reduction or clinical rejuvenation.

The external numerical observations support investigating topical CoQ10, but they do not establish comparative superiority of the candidate nanoemulsion. In the absence of primary biological data, conclusions must remain conditional. Subsequent controlled human studies could investigate hydration by corneometry, elasticity by cutometry, wrinkle depth by optical profilometry and transepidermal water loss. These require separate approval and predefined methods; they are not outcomes of the present protocol.

CONCLUSION

An integrated biological evaluation protocol has been defined for a CoQ10-loaded nanoemulsion using antioxidant, enzyme inhibition, cytocompatibility and cellular biomarker approaches. Published CoQ10 observations provide a quantitative rationale for this program. Experimental implementation and independent validation are necessary before biological efficacy, skin compatibility or clinical anti-aging benefits can be claimed.

DECLARATIONS

No new human or animal experiments were conducted.

REFERENCES

1. Rittié L, Fisher GJ. Natural and sun-induced aging of human skin. Cold Spring Harb PerspectMed. 2015;5(1):a015370. doi:10.1101/cshperspect.a015370.
2. Hoppe U, Bergemann J, Diembeck W, Ennen J, Gohla S, Harris I, et al. Coenzyme Q10, a cutaneous antioxidant and energizer. Biofactors. 1999;9(2–4):371–378. doi:10.1002/biof.5520090238.
3. Knott A, Achterberg V, Smuda C, Mielke H, Sperling G, Dunckelmann K, et al. Topical treatment with coenzyme Q10-containing formulas improves skin's Q10 level and provides antioxidative effects. Biofactors. 2015;41(6):383–390. doi:10.1002/biof.1239.
4. Brand-Williams W, Cuvelier ME, Berset C. Use of a free radical method to evaluate antioxidant activity. LWT Food Sci Technol. 1995;28(1):25–30. doi:10.1016/S0023-6438(95)80008-5.
5. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999;26(9–10):1231–1237. doi:10.1016/S0891-5849(98)00315-3.
6. Organisation for Economic Co-operation and Development. Test No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method. Paris: OECD Publishing; 2025. doi:10.1787/9789264242845-en.